PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 881 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Neil Gregory Almstead sold 881 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $76.45, for a total value of $67,352.45. Following the sale, the insider owned 115,196 shares in the company, valued at approximately $8,806,734.20. The trade was a 0.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Neil Gregory Almstead also recently made the following trade(s):

• On Thursday, January 8th, Neil Gregory Almstead sold 59 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total value of $4,510.55.
• On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $4,028.96.
• On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $79,494.48.
• On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $4,155.30.
• On Tuesday, January 6th, Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $98,419.05.
• On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.18, for a total transaction of $2,852,162.96.
• On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.44, for a total transaction of $6,001,672.32.

PTC Therapeutics Price Performance

NASDAQ PTCT opened at $77.59 on Tuesday. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market capitalization of $6.23 billion, a PE ratio of 9.06 and a beta of 0.49. The company has a fifty day moving average of $76.81 and a 200 day moving average of $63.11.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) EPS. Research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on PTCT shares. Royal Bank Of Canada downgraded shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price target for the stock from $82.00 to $91.00 in a report on Monday, December 1st. Wells Fargo & Company raised their target price on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. TD Cowen upped their price target on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, November 5th. Morgan Stanley reiterated an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a research report on Thursday. Finally, Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $77.27.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
• Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
• Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its stake in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 236 shares during the last quarter. Optiver Holding B.V. raised its stake in PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank lifted its holdings in PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares in the last quarter. IFP Advisors Inc boosted its stake in PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of PTC Therapeutics by 42.1% during the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 295 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.